Dronedarone: Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana

Translated title of the contribution: Dronedarone: A real innovation or just a valid second choice? How to disentangle between the guidelines, regulating agency and daily clinical practice

Alessandro Capucci, Federico Guerra, Cesare Antenucci, Roberto Antonicelli, Paolo Bocconcelli, Giuseppe Boriani, Paolo Busacca, Nino Ciampani, Stefano Della Casa, Domenico Gabrielli, Marcello Galvani, Massimo Margheri, Francesco Melandri, Maria Grazia Modena, Gian Piero Perna, Pierluigi Pieri, Giancarlo Piovaccari, Andrea Pozzolini, Claudio Rapezzi, Giovanni Quinto Villani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dronedarone is the antiarrhythmic drug with the most complete and wide literature preceding its marketing. Most of these studies showed a good efficacy along with an excellent risk profile, especially in low- and medium- risk patients. Recently, updates of European, American and even Italian guidelines gave dronedarone its own spot into the antiarrhythmic armamentarium, recommending its use both for rhythm control and rate control in non-permanent atrial fibrillation. In Italy, however, dronedarone prescription is still possible only when amiodarone is not tolerated, making dronedarone a mere second choice of its older "relative". Moreover, patients taking dronedarone must undergo a strict alanine aminotransferase and bilirubin follow-up, which usefulness in predicting drug-induced liver damage (probably idiosyncratic in nature and therefore unpredictable) is far from demonstrated. The aim of this review is to sum up actual evidences on dronedarone, describe how these evidences had been differently transposed by panel of experts and drug agencies into guidelines and recommendations, and define the current difficulties encountered by the cardiologist in the correct use of this new antiarrhythmic agent in clinical practice.

Original languageItalian
Pages (from-to)326-333
Number of pages8
JournalGiornale Italiano di Cardiologia
Volume13
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Guidelines
Amiodarone
Anti-Arrhythmia Agents
Marketing
Alanine Transaminase
Bilirubin
Pharmaceutical Preparations
Atrial Fibrillation
Italy
Prescriptions
dronedarone
Liver

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dronedarone : Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana. / Capucci, Alessandro; Guerra, Federico; Antenucci, Cesare; Antonicelli, Roberto; Bocconcelli, Paolo; Boriani, Giuseppe; Busacca, Paolo; Ciampani, Nino; Casa, Stefano Della; Gabrielli, Domenico; Galvani, Marcello; Margheri, Massimo; Melandri, Francesco; Modena, Maria Grazia; Perna, Gian Piero; Pieri, Pierluigi; Piovaccari, Giancarlo; Pozzolini, Andrea; Rapezzi, Claudio; Villani, Giovanni Quinto.

In: Giornale Italiano di Cardiologia, Vol. 13, No. 5, 05.2012, p. 326-333.

Research output: Contribution to journalArticle

Capucci, A, Guerra, F, Antenucci, C, Antonicelli, R, Bocconcelli, P, Boriani, G, Busacca, P, Ciampani, N, Casa, SD, Gabrielli, D, Galvani, M, Margheri, M, Melandri, F, Modena, MG, Perna, GP, Pieri, P, Piovaccari, G, Pozzolini, A, Rapezzi, C & Villani, GQ 2012, 'Dronedarone: Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana', Giornale Italiano di Cardiologia, vol. 13, no. 5, pp. 326-333. https://doi.org/10.1714/1065.11672
Capucci, Alessandro ; Guerra, Federico ; Antenucci, Cesare ; Antonicelli, Roberto ; Bocconcelli, Paolo ; Boriani, Giuseppe ; Busacca, Paolo ; Ciampani, Nino ; Casa, Stefano Della ; Gabrielli, Domenico ; Galvani, Marcello ; Margheri, Massimo ; Melandri, Francesco ; Modena, Maria Grazia ; Perna, Gian Piero ; Pieri, Pierluigi ; Piovaccari, Giancarlo ; Pozzolini, Andrea ; Rapezzi, Claudio ; Villani, Giovanni Quinto. / Dronedarone : Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana. In: Giornale Italiano di Cardiologia. 2012 ; Vol. 13, No. 5. pp. 326-333.
@article{0642b94d3ecf43fc8d9fe56fb4e8b5fb,
title = "Dronedarone: Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana",
abstract = "Dronedarone is the antiarrhythmic drug with the most complete and wide literature preceding its marketing. Most of these studies showed a good efficacy along with an excellent risk profile, especially in low- and medium- risk patients. Recently, updates of European, American and even Italian guidelines gave dronedarone its own spot into the antiarrhythmic armamentarium, recommending its use both for rhythm control and rate control in non-permanent atrial fibrillation. In Italy, however, dronedarone prescription is still possible only when amiodarone is not tolerated, making dronedarone a mere second choice of its older {"}relative{"}. Moreover, patients taking dronedarone must undergo a strict alanine aminotransferase and bilirubin follow-up, which usefulness in predicting drug-induced liver damage (probably idiosyncratic in nature and therefore unpredictable) is far from demonstrated. The aim of this review is to sum up actual evidences on dronedarone, describe how these evidences had been differently transposed by panel of experts and drug agencies into guidelines and recommendations, and define the current difficulties encountered by the cardiologist in the correct use of this new antiarrhythmic agent in clinical practice.",
keywords = "Acute liver failure, Antiarrhythmic drugs, Atrial fibrillation, Dronedarone, Drug-induced liver injury",
author = "Alessandro Capucci and Federico Guerra and Cesare Antenucci and Roberto Antonicelli and Paolo Bocconcelli and Giuseppe Boriani and Paolo Busacca and Nino Ciampani and Casa, {Stefano Della} and Domenico Gabrielli and Marcello Galvani and Massimo Margheri and Francesco Melandri and Modena, {Maria Grazia} and Perna, {Gian Piero} and Pierluigi Pieri and Giancarlo Piovaccari and Andrea Pozzolini and Claudio Rapezzi and Villani, {Giovanni Quinto}",
year = "2012",
month = "5",
doi = "10.1714/1065.11672",
language = "Italian",
volume = "13",
pages = "326--333",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "5",

}

TY - JOUR

T1 - Dronedarone

T2 - Una reale innovazione o solo una valida seconda scelta? Come districarsi tra linee guida, agenzie regolatorie e pratica clinica quotidiana

AU - Capucci, Alessandro

AU - Guerra, Federico

AU - Antenucci, Cesare

AU - Antonicelli, Roberto

AU - Bocconcelli, Paolo

AU - Boriani, Giuseppe

AU - Busacca, Paolo

AU - Ciampani, Nino

AU - Casa, Stefano Della

AU - Gabrielli, Domenico

AU - Galvani, Marcello

AU - Margheri, Massimo

AU - Melandri, Francesco

AU - Modena, Maria Grazia

AU - Perna, Gian Piero

AU - Pieri, Pierluigi

AU - Piovaccari, Giancarlo

AU - Pozzolini, Andrea

AU - Rapezzi, Claudio

AU - Villani, Giovanni Quinto

PY - 2012/5

Y1 - 2012/5

N2 - Dronedarone is the antiarrhythmic drug with the most complete and wide literature preceding its marketing. Most of these studies showed a good efficacy along with an excellent risk profile, especially in low- and medium- risk patients. Recently, updates of European, American and even Italian guidelines gave dronedarone its own spot into the antiarrhythmic armamentarium, recommending its use both for rhythm control and rate control in non-permanent atrial fibrillation. In Italy, however, dronedarone prescription is still possible only when amiodarone is not tolerated, making dronedarone a mere second choice of its older "relative". Moreover, patients taking dronedarone must undergo a strict alanine aminotransferase and bilirubin follow-up, which usefulness in predicting drug-induced liver damage (probably idiosyncratic in nature and therefore unpredictable) is far from demonstrated. The aim of this review is to sum up actual evidences on dronedarone, describe how these evidences had been differently transposed by panel of experts and drug agencies into guidelines and recommendations, and define the current difficulties encountered by the cardiologist in the correct use of this new antiarrhythmic agent in clinical practice.

AB - Dronedarone is the antiarrhythmic drug with the most complete and wide literature preceding its marketing. Most of these studies showed a good efficacy along with an excellent risk profile, especially in low- and medium- risk patients. Recently, updates of European, American and even Italian guidelines gave dronedarone its own spot into the antiarrhythmic armamentarium, recommending its use both for rhythm control and rate control in non-permanent atrial fibrillation. In Italy, however, dronedarone prescription is still possible only when amiodarone is not tolerated, making dronedarone a mere second choice of its older "relative". Moreover, patients taking dronedarone must undergo a strict alanine aminotransferase and bilirubin follow-up, which usefulness in predicting drug-induced liver damage (probably idiosyncratic in nature and therefore unpredictable) is far from demonstrated. The aim of this review is to sum up actual evidences on dronedarone, describe how these evidences had been differently transposed by panel of experts and drug agencies into guidelines and recommendations, and define the current difficulties encountered by the cardiologist in the correct use of this new antiarrhythmic agent in clinical practice.

KW - Acute liver failure

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Dronedarone

KW - Drug-induced liver injury

UR - http://www.scopus.com/inward/record.url?scp=84861075284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861075284&partnerID=8YFLogxK

U2 - 10.1714/1065.11672

DO - 10.1714/1065.11672

M3 - Articolo

C2 - 22539137

AN - SCOPUS:84861075284

VL - 13

SP - 326

EP - 333

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 5

ER -